Tigulixostat lowers uric acid levels
Advertisement
Tigulixostat significantly lowers the levels of serum uric acid (sUA) in gout patients with hyperuricemia versus placebo at all dose levels, according to results from a phase 2, dose-finding study. Also, the sUA lowering effect of tigulixostat appeared to be dose-dependent. Study participants tolerated well to the treatment with tigulixostat at all 3 dose levels.
The study was presented as the late-breaking posters at the ACR (American College of Rheumatology) Convergence 2021.
For more details, check out the full story on the link below:
Tigulixostat Lowers Uric Acid Levels In Gout Patients With Hyperuricemia: Study
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.